GSE101466   Details

GSE Accession GSE101466
Title Type I IFN and not TNF, is essential for cyclic di-nucleotide-elicited CTL by a cytosolic cross-presentation pathway
Submission Date 7/16/17
Last Update Date
Pubmed ID 28754303
Experiment Type Expression profiling by array
Contributor R,,Geffers; T Ebensen; I Liebich; D Lirussi; Kai Schulze; S Tritel; C,A,Guzman
Contact Name Robert Geffers
Contact E-mail
Organization Name HCI - Helmholtz Centre for Infection Research
Country Germany
Organism Mus musculus
Organism ID 7/14/17
Organism Synonym mouse;house mouse
Summary Dendritic cells are the initiators of the adaptive immune response, therefore its gene expression allow us to predict the responses to vaccination. We used bone marrow derived dendritic cells (BMDC) to analyze the gene expression that result from the exposure to adjuvants. We use model antigen OVA and cyclic di-AMP (CDA) as an adjuvant in order to characterize the genes involved in the activation of dendritic cells by CDA alone or when the antigen is present.; Cyclic di-nucleotides (CDN) are potent stimulators of innate and adaptive immune responses. Cyclic di-AMP (CDA) is a promising adjuvant that generates humoral and cellular immunity. The strong STING-dependent stimulation of type I IFN represents a key feature of CDA. However, recent studies suggested that this is dispensable for adjuvanticity. Here we demonstrate that stimulation of IFN-Îł-secreting CD8+ cytotoxic T lymphocytes (CTL) is significantly decreased after vaccination in the absence of type I IFN signaling. The biological significance of this CTL response was confirmed by the stimulation of MHC class I-restricted protection against influenza virus challenge. We show here that type I IFN (and not TNF-Îą) is essential for CDA-mediated cross-presentation by a cathepsin independent, TAP and proteosome dependent cytosolic antigen processing pathway, which promotes effective cross-priming and further CTL induction. Our data clearly demonstrate that type I IFN signaling is critical for CDN-mediated cross-presentation
Overall Design Cuadruplicates/Triplicates of different time points indicated below.
Platform ID
Timepoint Count 70
Timepoints gsm: [10005 y_, 10006 y_, 10021 y_, 10022 y_, 10025 y_, 10026 y_, 10041 y_, 10042 y_, 10045 y_, 10046 y_, 11001 y_, 11002 y_, 11005 y_, 11006 y_, 11022 y_, 11025 y_, 11026 y_, 11041 y_, 11042 y_, 11045 y_, 11046 y_, 12001 y_, 12006 y_, 12021 y_, 12025 y_, 12042 y_, 12045 y_, 12046 y_, 14001 y_, 14004 y_, 14005 y_, 14011 y_, 14012 y_, 14016 y_, 14027 y_, 14031 y_, 16029 y_, 17001 y_, 4001 y_, 4003 y_, 4021 y_, 4023 y_, 5001 y_, 5002 y_, 5005 y_, 5006 y_, 5021 y_, 5022 y_, 5025 y_, 5026 y_, 8002 y_, 8005 y_, 8006 y_, 8025 y_, 8029 y_, 8030 y_, 8049 y_, 8050 y_, 8053 y_, 8054 y_, 9001 y_, 9002 y_, 9005 y_, 9006 y_, 9021 y_, 9032 y_, 9033 y_, 9034 y_, 9037 y_, 9038 y_]
Disease thrombocytopenia-absent radius syndrome;
congenital disorder;
Disease ID DOID:14699;